

NOTICE TO CONVENE THE ANNUAL GENERAL MEETING

DANISH BIO - DANSK BIOTEK

(CVR no. 28 43 65 72)

Notice is hereby given to the Annual General Meeting of DANISH BIO - DANSK BIOTEK to be held on

Thursday, 11 May 2023, at 16:30 (CEST)
at Børsen, Slotsholmsgade, DK-1216 Copenhagen

The agenda is as follows:

- a) Election of Chairman of the Annual General Meeting
- b) Chairman's statement
- c) Approval of financial result for 2022
- d) Election of Chairman
- e) Election of Members of the Board
- f) Election of an Auditor
- g) Determination of membership fees for 2024
- h) Discussion of proposals
- i) Any other business

Re a) - Election of chairman of the Annual General Meeting

The Board proposes election of Attorney-at-Law, Thomas Holst Laursen as Chairman of the Annual General Meeting.

Re b) - Chairman's statement

Chairman Hans Schambye makes his statement regarding the previous year.

Re c) - Approval of financial result for 2022

The Board proposes that the Annual Report with the auditor's report for 2022 is approved.

Re d) - Election of Chairman

The Chairman is elected for a two-year period and may be re-elected.

The Board proposes that Hans Schambye continues as Chairman of the Board (2023-2025).

Re e) - Election of Members of the Board

The Board is elected for a two-year period and may be re-elected.

The Board proposes re-election of the following board members, who stand for election:

- Hans Schambye, CEO, Galecto Inc. (Chairman) (2023-2025)
- Alejandra Mørk, CEO, KLIFO A/S (2023-2025)
- Henrik Blou, CEO, Gubra (2023-2025)
- Lone Dybdal Nilsson, Vice President, Applied Research Agriculture & Industrial Biosolutions, Novozymes North America Inc. (2023-2025)
- Søren Møller, Managing Partner, Novo Holdings A/S (2023-2025)

The following board members continue:

- Thomas Kongstad Petersen, Chief Operating Officer, NMD Pharma (2022-2024)
- Adam Steensberg, Executive Vice President, Zealand Pharma (2022-2024)
- Mai-Britt Zocca, CEO & founder, IO Biotech ApS (2022-2024)

Re f) - Election of Auditor

The Board proposes re-election of EY Godkendt Revisionspartnerselskab, CVR no. 30 70 02 28, as the auditor of DANSK BIOTEK.

Re g) - Determination of membership fees for 2024

The Board proposes that the membership fee for 2024 shall be unchanged compared to 2023.

Re h) - Discussion of proposals

No proposals have been received.

Re i) - Any other business

Any other business.

- 0 -

Resolution requirements

The proposals set out in items a)-g) of the agenda must be adopted by a simple majority of votes.

Practical information

To ensure a smooth course of events at the Annual General Meeting, we encourage the Members to give proxy to the Chairman of the Board to vote on their behalf at the Annual General Meeting (power of attorney is attached to this notice). A scanned copy of the completed and signed power of attorney must be sent by e-mail to: ps@danskbiotek.dk no later than on Wednesday, 10 May 2023, at 10:00 (CEST).

Further, we encourage the Members to submit any questions well in advance of the Annual General Meeting.

- 0 -

Date: 11 May 2023

Kind regards

The Board of DANISH BIO - DANSK BIOTEK